{"id":559033,"date":"2021-08-23T10:58:01","date_gmt":"2021-08-23T10:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=559033"},"modified":"2021-08-23T10:58:01","modified_gmt":"2021-08-23T10:58:01","slug":"acute-ocular-pain-market-insight-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-ocular-pain-market-insight-epidemiology-and-market-forecast-2030_559033.html","title":{"rendered":"Acute Ocular Pain Market Insight, Epidemiology And Market Forecast -2030"},"content":{"rendered":"
\n
\"Acute<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Acute Ocular Pain Market\u2019 report deliver an in-depth understanding of the AOP, historical and forecasted epidemiology as well as the AOP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.<\/div>\n

Acute Ocular Pain Market<\/a><\/strong><\/p>\n

The AOP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM AOP market size from 2018–2030. The Report also covers current AOP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Acute Ocular Pain Market Outlook<\/strong><\/p>\n

Eye pain is a myriad of symptoms ranging from a sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from very simple refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. A feeling of discomfort or pain in the eye can be caused by a problem in the eye itself. It can also be caused by a problem involving any structures around the eye or referred pain from tissues with similar innervation as ocular tissues. Most ophthalmologic conditions producing ocular pains are associated with obvious ocular symptoms and signs like red-eye, photophobia, vision loss, or diplopia. Sometimes it poses a challenge to physicians when the pain is associated with a quiet eye or “white eye.”<\/p>\n

Pain associated with surgery, injury, infection, or inflammation at the front of the eye is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.<\/p>\n

Recently various drugs such as Dextenza, Inveltys, BromSite, and Lotemax have been approved to treat ocular inflammation and pain following ophthalmic surgery and cataract surgery. Dextenza is the first FDA-approved intracanalicular insert, a novel route of administration that delivers the drug to the eye’s surface without the need for eye drops. The drug is a preservative-free, resorbable hydrogel insert that delivers 0.4 mg of dexamethasone to treat postsurgical ocular inflammation and pain for up to 30 days with a single administration.<\/p>\n

Key Findings<\/p>\n